Clinical Trials
41 trialsA Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Masonic Cancer Center, University of Minnesota
ABCD-NK
Washington University School of Medicine
RIOT 4B
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
SELECT-CAR-NK
Essen Biotech
TIL Therapy in cSCC and MCC
Dana-Farber Cancer Institute
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
(RIOT 4A)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
ProbeTILity
Curacell Holding AB
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
The First Affiliated Hospital with Nanjing Medical University
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
TCRCure Biopharma Ltd.
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
ABILITY-1
Medicenna Therapeutics, Inc.
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
PragmaTIL
Vall d'Hebron Institute of Oncology
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
BAH250
Essen Biotech
BAH249
Essen Biotech
NEXTGENTIL-ACT
Vall d'Hebron Institute of Oncology
BAH248
Essen Biotech
BAH2472
Essen Biotech
BAH2472
Essen Biotech
COREVAX-1
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
RaC-Ad
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Immunotherapy for the Treatment of Advanced Solid Tumor
Tongji Hospital
The Maintenance Treatment of "ITIVA" in AML Patients
Henan Cancer Hospital
MC2TCR
Erasmus Medical Center
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Sheba Medical Center
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
St. Anna Kinderkrebsforschung